EGFR and diffuse intrinsic pontine glioma: Based on a pediatric sub-study nested with INTELLANCE 2, the FDA granted rare pediatric disease designation to the drug for the treatment of children with EGFR-amplified diffuse intrinsic pontine glioma (DIPG) [94].